MedTrace Logo

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

NCT03435341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 151

Last updated 2021-05-21

No results posted yet for this study

Summary

Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the survival and the quality of life, the clinical management strategies and the prognostic factors for survival related to the patient, in a prospective cohort of patients over 60 with AML diagnosis in Spain and treated outside of clinical trials; that is, under conditions of standard clinical practice.

The study will last 24 months in total from the inclusion of the first patient until the end of the last patient's follow-up

Conditions

  • Leukemia, Myeloid, Acute

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Montserrat Rafel, RML Advocacy · Celgene

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03435341 on ClinicalTrials.gov